Table 1 Phase I trials included in the analysis showing the name of the author, year of publication, number of patients enrolled in the trial, the intervention that was tested and the outcome
Author | Year | No of patients | Intervention | Outcome for CS patients |
|---|---|---|---|---|
Serrone et al.[12] | 2001 | 44 advanced sarcoma (2 CS) | Group A: IFOS short infusion + EPI | Not mentioned |
Group B: IFOS continuous infusion + EPI | ||||
Schwartz et al.[13] | 2005 | 38 advanced solid tumors with 6 sarcoma with at least 1 CS | LY293111 (Leucotriene-B4 receptor antagonist) | 1 SD |
Levine et al.[14] | 2006 | 51 advanced malignancies with 7 sarcoma with at least 1 CS | Veglin (VEGF antisense oligodeoxynucleotide) | 1 SD |
Lockhart et al.[15] | 2007 | 18 advanced malignancies (1 CS) | MAC-321 (analogue of docetaxel) | 1 SD |
Chawla et al.[16] | 2009 | 20 advanced sarcoma (1 CS) | Rexin-G (tumor-targeted retrovector) | Not mentioned |
Group A: 2 times a week | ||||
Group B: 3 times a week | ||||
Camidge et al.[17] | 2010 | 50 advanced malignancies with 11 sarcoma with at least 1 CS | PRO95780 (death receptor 5 antibody) | 1 SD |
Herbst et al.[18] | 2010 | 71 advanced malignancies with 9 sarcoma with at least 2 CS | rhApo2L/TRAIL (death receptor activator) | 2 PR |
Cohort 1: dose escalation | ||||
Cohort 2: treated at MTD | ||||
Olmos et al.[19] | 2010 | 29 advanced sarcoma (1 CS) | Figitumumab (IGF1R antibody) | 1 SD |
Qeuk et al.[20] | 2010 | 21 advanced solid tumors (1 CS) | Everolimus (mTOR inhibitor) and figitumumab (IGF1R antibody) | 1 SD |
Stroppa et al.[21] | 2010 | 8 advanced sarcoma (1 CS) | Doxorubicin + IFOS | Not mentioned |
Pacey et al.[22] | 2011 | 25 advanced solid tumors with at least 1 CS | Alvespimycin (heat shock protein 90 inhibitor) | 1 SD |